Loading
Sentiment · FY2026 Q2
As of FY2026 Q1, the Tellvest earnings-call sentiment score for Biogen (BIIB) is 4/10.
Biogen started FY2026 with revenue up 1.9% as growth products generated $851 million, now exceeding MS revenue for the first time. LEQEMBI market revenue reached $168 million up 74% year-over-year, and SPINRAZA High Dose was approved with strong early uptake. The Apellis acquisition added portfolio breadth but increased leverage. Operating income declined on higher investment spending, and FY2026 EPS guidance of $15.25-$16.25 was maintained as the business outlook confirmed tracking toward the upper end.
Scored from Biogen’s FY2026 Q1 earnings call. The newest quarter is available with Tellvest Pro.
Full Pro access for 30 days when you create a free account. No credit card required.
All prior quarters are free.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $2.45B | +2.9% | $1.83 | +7.0% | 76.2% | 20.7% | 10.9% | $695M |
| FY2025 Q1 | $2.43B | +6.1% | $1.64 | -39.3% | 76.2% | 30.1% | 9.9% | $212M |
| FY2025 Q2 | $2.65B | +7.3% | $4.35 |
| +8.7% |
| 64.2% |
| 22.2% |
| 24.0% |
| $144M |
| FY2025 Q3 | $2.45B | -0.4% | $3.17 | +19.2% | 64.3% | 25.0% | 19.0% | $1.23B |
| FY2025 Q4 | $2.28B | -7.1% | $-0.33 | -118.0% | 78.2% | -2.5% | -2.1% | $556M |
| FY2026 Q1 | $2.48B | +1.9% | $2.15 | +31.1% | 73.3% | 16.0% | 12.9% | $697M |
| FY2026 Q2 | $2.74B | +3.4% | $0.66 | -84.8% | 56.9% | 11.6% | 3.6% | $490M |